IMR Press / RCM / Volume 14 / Issue 2-4 / DOI: 10.3909/ricm0671

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
Divergent Effects of Various Diabetes Drugs on Cardiovascular Prognosis
Show Less
1 Southside Endocrinology, University of Alabama at Birmingham, Birmingham, AL
2 Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO
Rev. Cardiovasc. Med. 2013, 14(2-4), 107–122;
Published: 30 June 2013
This review discusses the current data on various antidiabetic medications and their effects on major adverse cardiovascular events (MACE). Diabetes mellitus is a potent independent risk factor for MACE, and this risk increases in proportion to the elevation of hemoglobin A1c. Available data suggest that tight glycemic control in patients with diabetes reduces microvascular complications, but has limited effect or may even increase the risk of MACE and other macrovascular complications. For individuals with type 2 diabetes mellitus (T2DM) drugs that reduce postprandial glucose (α-glucosidase inhibitors, incretin mimetics, quick-acting bromocriptine, dipeptidyl peptidase-4 inhibitors, and colesevelam) are associated with a decrease in MACE. Drugs that directly reduce insulin resistance (pioglitazone and metformin) are also associated with lesser but still significant decreases in MACE. Insulin, rosiglitazone (but not pioglitazone), and sulfonylureas (especially with glyburide and particularly the glyburide + metformin combination) are associated with increases in MACE. In summary, drugs that reduce postprandial glucose and improve insulin resistance without predisposing patients to hypoglycemia appear to both control hyperglycemia and improve cardiovascular prognosis. However, many of the traditional agents used for treating T2DM, such as insulin and sulfonylureas, do not improve cardiovascular prognosis despite improving hyperglycemia.
Major adverse cardiovascular events
Type 2 diabetes mellitus
Increta mimetics
DPP4 inhibitors
Quick-release bromocriptine
Insulin resistance
Postprandial hypergylcemia
Back to top